Sagimet Biosciences Inc. filed a Current Report on Form 8-K on November 12, 2026, announcing its financial results for the quarter ended September 30, 2026, and furnishing an updated investor presentation under Regulation FD.

Key Highlights

  • Reporting period: Financial results cover the quarter ended September 30, 2026.
  • Press release furnished: A press release dated November 12, 2026, announcing the quarterly results is attached as Exhibit 99.1.
  • Investor presentation updated: An updated slide presentation dated November 12, 2026, is attached as Exhibit 99.2 and will be used in meetings with investors from time to time, according to the filing.
  • Furnished, not filed: The filing states that the information in Items 2.02 and 7.01, including both exhibits, is furnished and "shall not be deemed 'filed'" for purposes of Section 18 of the Exchange Act.
  • Signed by CEO: The report was signed by David Happel, Chief Executive Officer, on November 12, 2026.

Sagimet Biosciences Furnishes Q3 2026 Results and Updated Investor Slides

Sagimet Biosciences Inc. (NASDAQ:SGMT), a Delaware-incorporated biosciences company headquartered in Foster City, California, submitted a Current Report disclosing its financial results for the third quarter ended September 30, 2026. According to the filing, the company issued a press release on November 12, 2026, which is incorporated by reference as Exhibit 99.1. The filing does not reproduce specific financial figures from the press release within the body of the 8-K itself.

Under Item 7.01, the filing discloses that the company updated an investor slide presentation, furnished as Exhibit 99.2. The filing states that "representatives of the Company will use the updated presentation in various meetings with investors from time to time." Both the press release and the presentation are described as furnished rather than filed, meaning they are not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, as the company disclosed.

The company is identified in the filing as an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. Its Series A Common Stock, with a par value of $0.0001 per share, is registered on The Nasdaq Global Market under the ticker symbol SGMT. The report was executed by Chief Executive Officer David Happel.

What Was Disclosed

Sagimet Biosciences filed an 8-K on November 12, 2026, furnishing a press release with Q3 2026 financial results and an updated investor presentation. Both items are furnished under Items 2.02 and 7.01, respectively, and are not deemed filed for Exchange Act liability purposes.